Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Technologies Introduces Next-Generation Sequencing Cancer Research Panels

Published: Tuesday, September 02, 2014
Last Updated: Tuesday, September 02, 2014
Bookmark and Share
High-performance ClearSeq AML to be followed by series of focused, comprehensive gene panels for cancer research.

Agilent Technologies Inc. today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.

Designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University, ClearSeq AML provides comprehensive coverage of mutations and enables swift progression of sample processing to analysis in less than 48 hours. The AML gene panel will be followed by the release of additional ClearSeq panels for cancer research throughout the coming months.

"We are pleased to introduce the ClearSeq family of products, a comprehensive set of targeted NGS gene panels for cancer research," said Jacob Thaysen, vice president and general manager of Agilent's Diagnostics and Genomics Group. "ClearSeq NGS panels are expert-identified products that will provide customers with a complete end-to-end anatomical-to-molecular genomics portfolio that includes solutions ranging from IHC for cancer diagnosis to NGS for cancer research."

Acute myeloid leukemia (AML) is the most common myeloid neoplasm affecting adults, and the role of chromosomal structural variations in its molecular pathogenesis is well documented. In recent years, next-generation sequencing has led to a revolution in the study of hematological malignancies and shown that insertions, deletions (indels) and mutations play an essential part in the pathogenesis of AML. Genetic information coupled with standard anatomical findings has provided a deeper characterization and classification of AML.

ClearSeq AML provides 99.9 percent design coverage of targeted coding exons. Agilent's high-performance cancer panels enable the study of more complex genomic alterations in cancer, and deliver quick and accurate identification of relevant information. ClearSeq panels are based on SureSelect and HaloPlex technology, offering superior sensitivity and accuracy compared with other hybridization or PCR-based methods, thus minimizing the risk of false-positive results. ClearSeq panels can be easily incorporated into routine laboratory workflows. Sequence data analysis and mutation reporting can be completed in three simple steps using Agilent's SureCall software.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Names CNAG as Certified Provider of Target-Enrichment Services
Centro Nacional de Análisis Genómico (CNAG) in Barcelona is one of Europe’s leading genome analysis centers.
Monday, February 23, 2015
Agilent Combines Its Life Sciences and Diagnostics Businesses
Decision follows Agilent's announcement that it plans to separate the company into two independent publicly traded companies.
Thursday, September 19, 2013
Scientific News
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.
Far-reaching Genetic Study of 1,000 UK People
300,000 gene variants from 1,000 people made publically available via F1000Research.
DNA Alterations as Among Earliest to Occur in Lung Cancer Development
Genetic footprints of precancer detectable in some blood samples.
Targeting DNA
Protein-based sensor could detect viral infection or kill cancer cells.
Genetic Sleuthing
Sabeti team applies Ebola methods to shed light on spread of Lassa fever.
Seeking “Gold Standard” Wastewater Treatments
Metagenomic analyses lend insights into how microbes break down wastewater contaminants.
Using Genetic Sequencing to Manage Cancer in Children
A team of scientists have investigated the feasibility of incorporating clinical sequencing information into the care of young cancer patients.
Big Data Tool to Reveal Immune System Role in Diseases
Researchers from the Icahn School of Medicine at Mount Sinai and Princeton University have designed a new online tool that predicts the role of key proteins and genes in diseases of the human immune system.
Next-Gen Genomic Tests Identify Brain-Eating Amoeba
New UCSF center aims to make tests more affordable and accessible to doctors.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos